The Netherlands
Merus N.V., a biotechnology firm founded in 2003, is headquartered in The Netherlands. The company is at the forefront of developing innovative oncology solutions using its proprietary Biclonics® bispecific antibody therapeutics. This pioneering approach enables simultaneous multi-targeted tumor attacks, enhancing the immune response and inhibiting tumor growth pathways.
With over a decade of research and development, Merus N.V. has several promising drug candidates currently in clinical trials. The firm's commitment to revolutionizing cancer treatment is underscored by its strategic international partnerships and presence in both European and US markets. Additionally, its NASDAQ listing since 2016 highlights its financial standing and industry credibility.
Recently, the company secured a substantial $400.20M Post-IPO Equity investment, reflecting strong investor confidence and positioning Merus N.V. for continued growth in the Biotechnology and Health Care sectors. This funding is poised to advance their mission of developing best-in-class cancer therapeutics.
